Table 1.
Patient characteristics and Urine Drug Screen (UDS) results stratified by Xylazine Presence, Miami, Florida 2023.
| Variable | Total (n = 59) | Xylazine + (n = 33) | Xylazine – (n = 26) | p-value |
|---|---|---|---|---|
| Age (mean, IQR) | 42.5 (11) | 42.2 (10) | 42.9 (15) | 0.597 |
| Sex | 0.652 | |||
| Male | 39 (66.1 %) | 21 (63.6 %) | 18 (69.2 %) | |
| Female | 20 (33.9 %) | 12 (36.4 %) | 8 (30.8 %) | |
| Gender | 0.573* | |||
| Man | 38 (64.4 %) | 21 (63.6 %) | 17 (65.4 %) | |
| Woman | 20 (33.9 %) | 12 (36.4 %) | 8 (30.8 %) | |
| Transgender Woman | 1 (1.7 %) | 0 (0 %) | 1 (3.8 %) | |
| Race/Ethnicity | 0.092* | |||
| Non-Hispanic White | 34 (57.6 %) | 23 (69.7 %) | 11 (42.3 %) | |
| Hispanic | 22 (37.3 %) | 9 (29.3 %) | 13 (50.0 %) | |
| Non-Hispanic Black | 3 (5.1 %) | 1 (3.0 %) | 2 (7.7 %) | |
| Other | 0 (0 %) | 0 (0 %) | 0 (0 %) | |
| Housing status | 0.018 | |||
| Apartment/House | 24 (40.7 %) | 9 (27.3 %) | 15 (57.7 %) | |
| Unhoused | 35 (59.3 %) | 24 (72.3 %) | 11 (42.3 %) | |
| Reason for visit | 0.536* | |||
| Buprenorphine only | 39 (66.1 %) | 19 (57.6 %) | 20 (76.9 %) | |
| Wound care only | 14 (23.7 %) | 9 (27.3 %) | 5 (19.2 %) | |
| Wound care+ Buprenorphine | 2 (3.4 %) | 2 (100 %) | 0 (0 %) | |
| Other | 3 (5.2 %) | 2 (6.1 %) | 1 (3.8 %) | |
| HIV status | 1.00* | |||
| Positive | 5 (8.5 %) | 3 (9.1 %) | 2 (7.7 %) | |
| Negative | 54 (91.5 %) | 30 (90.9 %) | 24 (92.3 %) | |
| HCV antibody status | 0.014 | |||
| Positive | 31 (52.5 %) | 22 (66.7 %) | 9 (34.6 %) | |
| Negative | 29 (47.5 %) | 11 (33.3 %) | 17 (65.4 %) | |
| Wounds present | ||||
| Yes | 24 (40.7 %) | 18 (54.5 %) | 6 (23.1 %) | 0.008 |
| No | 33 (55.9 %) | 13 (39.4 %) | 20 (76.9 %) | |
| Drugs present on UDS | ||||
| Fentanyl | 41 (81.4 %) | 31 (93.9 %) | 17 (65.4 %) | 0.005 |
| Cocaine | 29 (49.2 %) | 16 (48.5 %) | 13 (50.0 %) | 0.908 |
| Cannabis | 26 (44.1 %) | 14 (42.4 %) | 12 (46.2 %) | 0.775 |
| Amphetamine | 6 (10.2 %) | 5 (15.2 %) | 1 (3.8 %) | 0.215* |
| Buprenorphine | 8 (13.6 %) | 3 (9.1 %) | 5 (19.2 %) | 0.284* |
| Benzodiazepines | 17 (28.8 %) | 10 (30.3 %) | 7 (26.9 %) | 0.776 |
| MDMA | 14 (23.7 %) | 13 (39.4 %) | 1 (3.8 %) | 0.002* |
| Oxycodone | 2 (3.4 %) | 2 (6.1 %) | 0 | 0.499* |
| Tramadol | 1 (1.7 %) | 1 (3.0 %) | 0 | 1.000* |
| Ethyl Glucuronide | 11 (18.6 %) | 5 (15.2 %) | 6 (23.1 %) | 0.438 |
| Opiates 300ᵃ | 6 (10.2 %) | 4 (12.1 %) | 2 (7.7 %) | 0.685* |
| Opiates 2000ᵇ | 2 (3.4 %) | 1 (3.0 %) | 1 (3.8 %) | 1.000* |
| Methadone | 5 (8.5 %) | 2 (6.1 %) | 3 (11.5 %) | 0.386* |
| Methamphetamines | 8 (13.6 %) | 7 (21.2 %) | 1 (3.8 %) | 0.067 |
| Opioids detected in UDS | ||||
| No | 8 (13.6 %) | 2 (6.1 %) | 6 (23.1 %) | 0.058 |
ᵃopiates detected at a cutoff concentration of 300 mg/dL.
ᵇopiates detected at a cutoff concentration of 2000 mg/dL.